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Background: Leptin and adipocyte-fatty acid binding protein (A-FABP) are produced by white adipose tissue and may
play a role in chronic inflammation in Multiple Sclerosis (MS). To assess leptin and A-FABP in relapsing and progressive
forms of MS.
Methods: Adipokine levels were measured in untreated adult relapsing-remitting MS (RRMS), secondary progressive MS
(SPMS), primary progressive MS (PPMS) and Healthy control (HC). Pediatric-onset MS (POMS) and pediatric healthy con-
trols (PHC) were also assessed. Leptin and A-FABP levels were measured in serum by ELISA. Groups were compared using
linear mixed-effects model.
Results: Excluding two patients with Body Mass Index (BMI) > 50, a significant difference in leptin level was found
between RRMS and HC controlling for age (p = 0.007), SPMS and HC controlling for age alone (p = 0.002), or age and
BMI (p = 0.007). A-FABP levels were higher in SPMS than HC (p = 0.007), controlling for age and BMI. Differences in A-
FABP levels between POMS and PHC was observed after controlling for age (p = 0.019), but not when BMI was added to
the model (p = 0.081).
Conclusion: Leptin and A-FABP levels are highest in SPMS compared to HC, suggesting a role in pathogenesis of this
disease subtype. A-FABP levels are increased in POMS patients and may play a role in the early stages of disease.
Keywords: 41. Multiple sclerosis, 132. Autoimmune disease, 175. NeuroendocrinologyBackground
Multiple sclerosis (MS) is a T-cell mediated inflammatory
disease, involving both innate and adaptive immunity [1].
Obesity has been associated with a chronic inflammatory
state, due to the secretion of pro-inflammatory proteins in
the blood [2]. Increased body mass index (BMI) at the age
of 18 is associated with a two-fold increase in the risk of
MS [3]. A potential reason for the impact of obesity on dis-
ease is the associated increase in adipokines, a family of
molecules with effects on inflammatory and autoimmune
diseases [4].
Leptin is involved in the regulation of food-intake, en-
ergy expenditure, and inflammation. In addition to white
adipose tissue (WAT), leptin is also produced by lym-
phocytes [5,6]. Leptin levels have been investigated in* Correspondence: tchitnis@partners.org
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reproduction in any medium, provided the orrelapsing remitting (RR) MS and secondary progressive
(SP) MS patients with differing results [7–9].
Serum adipocyte fatty acid-binding protein (A-FABP)
belongs to a family of small cytoplasmic proteins. A-
FABP is produced by WAT and monocytes, and its
expression is enhanced by toll-like receptor-2 (TLR-2)
stimulation [10]. A-FABP is predictive of poor outcome
in ischemic stroke, suggesting it may play a role mediating
stroke-associated inflammation [11]. To date, no studies
have addressed the role of A-FABP in MS.
Leptin is produced by lymphocytes and can promote the
activation of monocyte-macrophages while A-FABP is
produced by macrophages. Therefore, leptin and A-FABP
may respectively affect the adaptive and innate arms of the
immune system, potentially playing critical roles in differ-
ent stages of MS. We therefore chose to investigate these
two adipokines in relapsing and progressive MS patients.
The aim of this study is to evaluate the levels of leptin
and A-FABP in different categories of MS patientsl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between protein levels and MS may vary according to de-
velopmental age, levels in MS patients were compared to
HC both in adult and pediatric onset patients. Finally, in
order to investigate a potential role of adipokines in clinical
relapses, adipokine levels were studied in patients before or
during a relapse.Methods
Patients
Five groups of subjects contributed to the three main
analyses of our study.Adult-onset MS (AOMS)
The first group of subjects included patients with onset
of MS after age 18 from the Comprehensive Longitu-
dinal Investigation of Multiple Sclerosis at the Brigham
and Women’s Hospital (CLIMB) [12]. This study has en-
rolled and followed longitudinally patients since 2000,
with annual standardized clinical exams, MRIs and stored
blood samples. Patients were included in this study if they
met the following diagnostic criteria: clinically definite
RRMS or primary progressive MS (PPMS), by the 2005
McDonald criteria [13]. SPMS patients were identified
using the following criteria: relapsing onset of disease,
EDSS ≥ 3.0 and evidence of sustained disease progression.
Subjects included in this study had not been exposed to
intravenous steroids or disease modifying treatment (DMT)
for at least 30 days prior to the blood sample, and had full
anthropometric data (height and weight) recorded within a
year of blood sample collection. RRMS patients were not
treated for personal choice or because they were undergo-
ing a medication wash-out period.Adult Healthy Controls (AHC)
As a comparison group, a set of healthy controls (HC)
enrolled in the Phenogenetic Project at the Brigham and
Women’s Hospital was recruited. HC were matched for
age and sex, and both a blood sample and anthropomet-
ric data were available.Pediatric-onset MS (POMS)
The second group in our study consisted of pediatric-
onset MS patients (POMS). These patients were seen at
the Partners Pediatric MS Center at the Massachusetts
General Hospital (MGH) for Children. Pediatric MS was
defined according to the operational definition estab-
lished by the International Pediatric Multiple Sclerosis
Study Group [14]. POMS patients were included if they
were untreated by either steroid or DMT for at least 30 days
prior to the blood sample collection and had full anthropo-
metric data available.Pediatric Healthy Controls (PHC)
Age and sex matched pediatric healthy controls (PHC)
were also enrolled from MGH for Children.
Relapsing AOMS
The third group of patients consisted of CLIMB patients
who had blood samples collected prior (Pre-relapse group)
or during a relapse (Relapse group). A relapse was defined
as the occurrence of a new neurological disturbance lasting
at least twenty-four hours [15]. Samples were considered
prior to a relapse if the blood was drawn within ninety days
before a relapse. For these patients, a sample during remis-
sion (if available) was also analyzed for comparison. A re-
mission sample was defined by no relapses occurring six
months before, or after the collected sample. Seven patients
in the pre-relapse group and one in the relapse group were
untreated. The demographic and clinical characteristics of
all three groups of subjects are provided in Table 1. Clinical
data for all MS patients were validated by a member of the
study staff (SM). Institutional Review Board approval was
granted by the Partners Human Research Committee.
ELISA
We measured leptin in serum by ELISA (human Leptin,
R&D system) with an intra-assay coefficient of variant
of 3.2% and an inter-assay coefficient of variant of
8.2%. A-FABP was measured in serum by ELISA (human
A-FABP, BioVendor) with an intra-assay coefficient of
variant of 1.4% and an inter-assay coefficient of variant of
6.4%. For each measure, the experiments were completed
in batches of up to 40 patients per batch. Some samples
were measured in multiple batches. All the samples were
assayed in duplicates.
Statistical analysis
To assess differences between RRMS, SPMS, PPMS, and
HC in the AOMS subjects, log-transformed leptin and
log-transformed A-FABP levels were compared using a
linear mixed-effects model to account for repeated mea-
sures on some of the patients. Log-transformation was
used due to the skew of the data. For each outcome, the
analysis was completed controlling for batch/age and
batch/age/BMI. BMI was calculated as body weight(kg)/
height(m [2]). Analyses are reported with and without con-
trolling for BMI because BMI may be either an intermedi-
ary or a result of the relationship between MS status and
leptin/A-FABP rather than a confounder. Pairwise differ-
ences among the groups were calculated and a Bonferroni
alpha level of 0.0083 was used to assess statistical signifi-
cance. The interaction between BMI and MS status in the
linear mixed-effects model was assessed. Pearson Correl-
ation was used to assess the relationship between leptin
and A-FABP levels in both the AOMS and HC subjects,
using last available batch measured level where repeated
Table 1 Demographic characteristics







Healthy controls Pediatric onset MS Pediatric healthy
controls
Pre- relapse patients Relapse patients
N 20 13 12 48 12 10 18 11
Males N (%) 3 (15.0) 6 (46.2) 1 (8.3) 14 (29.2) 4 (33.3) 3 (30.0) 3 (16.7) 2 (18.2)
Age Mean (SD) 43.0 (8.9) 56.9 (7.7) 53.6 (12.5) 45.1 (13.1) 13.9 (2.3) 11.4 (3.3) 40.7 (11.3) 36.4 (10.9)
Hispanic N (%) 0 (0) 0 (0) 0 (0) 0 (0) 1 (8.3) 1 (10.0) 1 (5.6) 0 (0)
White N (%) 18 (90.0) 13 (100) 12 (100) 44 (91.7) 10 (83.3) 8 (80.0) 17 (94.4) 9 (81.8)
BMI Mean (SD) 27.7 (5.0) 30.1 (5.4) 30.7 (7.9) 26.0 (6.2) 26.9 (9.2) 21.4 (3.7) 26.2 (4.4) 29.5 (6.3)
EDSS Median (Range) 2 (0–4.5) 6 (1.5-7) 5.0 (2.5-8.0) 1.75 (0–2) 1.75 (0–6) 2 (0–3.5)
Disease Duration
Mean (SD)
11.3 (9.3) 14.5 (7.6) 19.9 (9.6) 1.75 (2.1) 8.1 (6.6) 8.2 (5.5)
Leptin (pg/ml)
Mean (SD)
23,462.3 (27,708.9) 17,924.6 (14,009.8) 40,412.6 (27,951.8) 13,840.5 (18,447.6) 27,357.3 (20,207.4) 11,177.0 (11,484.7) 24,381.6 (20,350.1) 37,587.1 (26,465.4)
A-FABP (ng/ml)
Mean (SD)
21.2 (14.6) 34.9 (18.9) 38.8 (15.5) 18.4 (18.8) 26.7 (18.0) 14.7 (7.6) 17.5 (10.5) 27.7 (13.1)
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leptin/A-FABP levels association with the clinical mea-
sures (EDSS and disease duration) was assessed using a
linear mixed-effects model to account for the repeated
measurements. The differences between POMS and
PHCs were estimated using the same models as above.
Pearson correlation was used to test the relationships be-
tween leptin and A-FABP levels and clinical measure-
ments (EDSS and disease duration) within the POMS
subjects. To assess the differences in leptin and A-FABP
levels when stable and prior to a relapse/during a relapse,
linear mixed effects models with a patient specific effect
were fit in both the Pre-relapse and Relapse groups separ-
ately. For all analyses, p < 0.05 was considered statistically
significant and 0.05 < p < 0.1 was considered a trend to-
wards statistical significance. All statistical analyses were
completed in the statistical software R (www.r-project.org)
with the nlme library [16].
Results
Comparisons of AOMS and HC
Leptin expression was compared in three groups of
AOMS patients (RRMS, PPMS, SPMS) with HC (Table 2
and Figure 1a). In the main analysis controlling for
batch/age, a statistically significant difference among the
groups was observed (p = 0.008). When the pairwise com-
parisons were investigated, leptin levels were significantly
higher in SPMS compared to HC (p = 0.003). After control-
ling for batch/age/BMI, the differences between the groups
showed a trend towards statistical significance (adjusted
p = 0.054), and the SPMS group showed the highest levels
of expression. In this model, the association between leptin
and BMI was also statistically significant (p < 0.0001).
Two patients with BMI > 50 were then excluded from
the analysis, given an observed outlier effect in this co-
hort where all other BMIs were under 40. Subsequently,
a statistically significant difference among groups wasTable 2 Comparisons of log-transformed leptin and log-trans
healthy controls
Adjust
Leptin Healthy controls Referen
Relapsing remitting MS 0.66 +/
Secondary progressive MS 1.01 +/
Primary progressive MS 0.16 +/
Four group comparison p-value 0.008
A-FABP Healthy controls Referen
Relapsing remitting MS 0.07 +/
Secondary progressive MS 0.49 +/
Primary progressive MS 0.26 +/
Four group comparison p-value 0.117
Legend: The estimated difference +/− standard error (p-value) between each group
A-FABP = adipocyte fatty acid binding protein, BMI = body mass index.observed in both analyses (Table 3). Controlling for batch/
age, both RRMS and SPMS patients had significantly
higher levels of leptin compared to HC (p = 0.007 RR, p =
0.002 SP). Controlling for batch/age/BMI, the difference
between SPMS and HC remained significant (p = 0.007).
Additionally, leptin levels were significantly higher in
SPMS than in PPMS patients (p = 0.0068).
When the association between leptin levels in MS sub-
groups and their BMI was investigated in the entire sam-
ple, a trend towards statistical significance (p = 0.065) was
observed. The association between BMI and leptin was
the lowest in SPMS patients (Additional file 1: Table S1).
As with the previous analysis, the extreme BMI patients
had a large impact on these results because the BMI by
MS subgroup interaction was also not statistically sig-
nificant when excluding those with BMI > 50 (p = 0.87)
(Additional file 1: Table S2).
The A-FABP analysis showed no significant group differ-
ences in the four-group (RRMS, SPMS, PPMS, and HC)
comparison after adjusting for batch/age and batch/age/
BMI (Table 2 and Figure 1b). Excluding high BMI patients,
the model adjusting for batch/age showed a statistically sig-
nificant difference among the groups (Table 3). SPMS pa-
tients had the highest levels of A-FABP, and the difference
between SPMS and HC was statistically significant (p =
0.003). Adjusting for batch/age/BMI, there was a trend
towards a statistically significant effect of group (p = 0.062).
When the interaction between A-FABP in each group
and BMI was assessed in the entire sample, a statistically
significant difference in the association between BMI and
A-FABP based on group was observed (interaction p =
0.019). SPMS patients had significantly lower associations
between BMI and A-FABP compared to either HC or
RRMS patients (Additional file 1: Table S1). In patients
with BMI < 50, the association between BMI and A-FABP
levels by MS subgroup interaction was not statistically sig-
nificant (p = 0.63) (Additional file 1: Table S2). A positiveformed A-FABP levels in adult onset MS patients to
ed for batch and age Adjusted for batch, age and BMI
ce Reference
− 0.28 (0.020) 0.43 +/− 0.23 (0.067)
− 0.33 (0.003) 0.59 +/− 0.28 (0.041)
− 0.34 (0.63) −0.09 +/− 0.28 (0.74)
0.054
ce Reference
− 0.17 (0.69) 0.02 +/− 0.17 (0.90)
− 0.21 (0.021) 0.34 +/− 0.21 (0.098)
− 0.18 (0.16) 0.15 +/− 0.18 (0.41)
0.403
































Figure 1 Leptin and A-FABP levels expressed as mean and SD. a) leptin levels expressed as mean and SD; b) A-FABP levels expressed as mean
and SD. A-FABP= adipocyte-fatty acid binding protein, RR=relapsing remitting, SP=secondary progressive, PP=primary progressive, HC=healthy
control, MS=multiple sclerosis, SD=standard deviation.
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within both the AOMS (p = < 0.001) and HC (p = 0.003)
subjects. However when stratifying the AOMS patients by
disease subtype, a significant correlation was observed only
in the relapsing subjects (RRMS p = 0.002) (Additional
file 1: Table S3). When assessing the relationship be-
tween the clinical measures (EDSS and disease duration)
and Leptin/A-FABP within the AOMS subjects, we ob-
served a statistically significant association between EDSS
and A-FABP (p = 0.024), after adjusting for batch/age.
However, after adjusting for batch/age/BMI no significant
association was observed in the AOMS samples.Comparisons of POMS and PHC
When leptin levels were compared in POMS patients
and PHC, no significant differences were observed in
either of the analyses (Table 4). The differences between
the POMS and PHC were of a similar magnitude as the
adult analysis, although the sample size was smaller. No
significant interaction between leptin levels, BMI and
MS status was observed (p = 0.14).Table 3 Comparisons of log-transformed leptin and log-trans
BMI < 50 to healthy controls
Adjust
Leptin Healthy controls Referen
Relapsing remitting MS 0.74 +/
Secondary progressive MS 1.07 +/
Primary progressive MS 0.22 +/
Four group comparison p-value 0.003
A-FABP Healthy controls Referen
Relapsing remitting MS 0.15 +/
Secondary progressive MS 0.63 +/
Primary progressive MS 0.33 +/
Four group comparison p-value 0.020
Legend: The estimated difference +/− standard error (p-value) between each group
A-FABP = adipocyte fatty acid binding protein, BMI = body mass index.POMS patients had significantly higher A-FABP levels
than controls in the model controlling for batch/age.
Controlling for BMI as well, the MS patients had higher
levels, but the difference was not statistically significant.
No significant interaction between A-FABP, BMI and
group was observed (p = 0.77). A significant correlation
was observed between the Leptin and A-FABP within
the pediatric subjects (p = 0.036). When assessing the re-
lationship between adipokine levels and clinical mea-
sures in the POMS subjects, no significant correlations
were observed for either leptin or A-FABP.Effect of relapse on adipokine levels
To investigate whether adipokine levels change near a re-
lapse in AOMS patients, samples collected within 90 days
prior to a relapse (pre-relapse group) or during a relapse
(relapse group) were compared to the subject’s own remis-
sion samples. Neither leptin nor A-FABP showed significant
differences between pre-relapse and remission measure-
ments (estimated increase due to relapse for leptin = 0.081,
p = 0.67 and for A-FABP = 0.064, p = 0.44) or betweenformed A-FABP levels in adult onset MS patients with
ed for batch and age Adjusted for batch, age and BMI
ce Reference
− 0.27 (0.007) 0.38 +/− 0.23 (0.098)
− 0.33 (0.002) 0.76 +/− 0.28 (0.0074)
− 0.33 (0.49) −0.14 +/− 0.27 (0.61)
0.014
ce Reference
− 0.16 (0.37) 0.058 +/− 0.16 (0.72)
− 0.21 (0.003) 0.54 +/− 0.20 (0.007)
− 0.17 (0.062) 0.18 +/− 0.17 (0.30)
0.062
and the healthy controls are presented. MS =multiple sclerosis,
Table 4 Comparisons of log-transformed leptin and log-transformed A-FABP levels in pediatric onset MS patients to
pediatric healthy controls
Adjusted for batch and age Adjusted for batch, age and BMI
Leptin Healthy controls Reference Reference
Pediatric onset MS 1.09 ± 0.73 0.11 ± 0.57
p-value 0.15 0.86
A-FABP Pediatric healthy controls Reference Reference
Pediatric onset MS 0.74 ± 0.28 0.49 ± 0.26
p-value 0.019 0.081
Legend: The estimated difference +/− standard error between each group and the healthy controls are presented. MS =multiple sclerosis, A-FABP = adipocyte fatty
acid binding protein, BMI = body mass index.
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due to relapse for leptin = 0.36, p = 0.10 and for A-FABP =
0.085, p = 0.40).
Discussion
Although leptin has been previously studied, this is the
first study of A-FABP in MS patients to our knowledge.
We found that A-FABP and leptin levels were significantly
higher in SPMS patients with a BMI ≤ 50, compared to
controls when adjusting for age and BMI. Leptin levels
were increased in adult RRMS compared to controls when
adjusting for age only, but not when BMI was added to the
model. Furthermore, we found a positive correlation be-
tween leptin and A-FABP in RRMS patients and POMS,
but not in SPMS. Finally, A-FABP levels were higher in
POMS patients than in controls when adjusting for age,
but not when we additionally adjusted for BMI. There were
no differences in leptin and A-FABP levels in patients be-
fore or during a relapse compared to the remission phase.
Our analysis performed after excluding the two pa-
tients with BMI > 50 is preferred, as the rest of our co-
hort had a BMI < 40 and these two outliers had high
influence on the results. Normal BMI is between 18.5-
24.9, and obesity is defined as a BMI of 30 or higher
[17]. Mean BMI for U.S. men and women in 2009–2010
is 28.7 [18]. Therefore, these two outliers represent far
extremes of obesity well beyond the normal range. It is
possible that adipokine levels may be different in ex-
tremely obese persons with MS.
BMI could be either a confounder of the effect of MS
on adipokines or an intermediary between MS and the
adipokines, therefore in our analysis we controlled for
age/batch alone and age/batch/BMI in separate models
in order to evaluate these relationships. The age/batch
model estimates the full group differences, while the age/
batch/BMI model estimates the direct effect of group
membership on adipokines eliminating any effect of BMI.
Leptin is an adipokine affecting both the innate and
adaptive immune system. It acts as an acute-phase react-
ant and it can be induced by other inflammatory media-
tors such TNF, IL-1 and IL-6 [19,20]. In the innate system,it promotes the activation of the monocyte-macrophage
lineage, activating phagocytosis and secretion of proin-
flammatory cytokine and leukotriene B [21,22]. Leptin
regulates the immune response towards a T helper 1
(Th1) profile [23]. Leptin deficient mice (ob/ob) are resist-
ant to the induction of experimental autoimmune enceph-
alomyelitis (EAE), the animal model of MS [24].
In each model, we found the highest level of leptin in
SPMS. The differences between SPMS/RRMS patients
and healthy controls decreased controlling for BMI in
addition to age and batch. This result shows that some
of the differences in leptin expression levels may be due
to the increased BMI in RRMS/SPMS compared to con-
trols. Interestingly, the difference between SPMS and
HC remained statistically significant even after control-
ling for BMI, but the difference between RRMS and HC
was no longer statistically significant. A potential explan-
ation for these results is that during early stages of dis-
ease, leptin levels may be correlated with adipose tissue
mass, but with disease progression and age the increased
levels of leptin are no longer dependent on adipose tissue
and may be produced by other cells including monocytes
[10]. Levels of leptin in PPMS were similar to HC, and sig-
nificantly lower than in SPMS in the model controlling for
batch/age/BMI, suggesting that this adipokine is differen-
tially involved in the PP and SP forms of progressive MS,
as has been observed for other biomarkers [25]. Leptin
levels in SPMS patients have been investigated in a previ-
ous study. They found a decrease of leptin and IL-6 levels
after IFN-beta 1b 6 months therapy in a group of SPMS
patients, suggesting a possible role of leptin as a marker of
response to treatment in the progressive stage of the dis-
ease [9]. Our samples were gathered in untreated patients
(off steroid or DMTs), therefore our findings confirm and
strengthen the concept of a possible involvement of leptin
in the pathogenesis of SPMS.
A prior study found that leptin levels decrease two
months after initiation of IFN- beta1a and increase before
a clinical exacerbation in RRMS patients [8]. In a separate
study, a higher serum leptin level was observed during re-
mission in RRMS patients than in controls [26]. We did
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or pre-relapse phase compared to remission phases in the
same patients, suggesting that acute exacerbations do not
cause significant fluctuations in leptin levels.
A-FABP is an adipokine mediating intracellular fatty acid
trafficking [27]. It is produced by adipocytes and mono-
cytes after TLR-2 and 4 stimulation [10]. In humans A-
FABP levels in the bloodstream are correlated with high
obesity index, blood pressure, plasma glucose and reduced
High-density lipoprotein cholesterol (HDL) [28]. Indeed a
recent study has found a correlation with low-density lipo-
protein cholesterol (LDL) and inflammatory MRI mea-
sures [29]. A-FABP is associated with stroke in humans
and is predictive of a poor outcome [11]. A-FABP, potenti-
ates LPS-induced inflammation, forming a positive feed-
back with the C-Jun-NH2-terminal kinase (JNK), involved
in the A-FABP gene transcription, perpetuating the inflam-
matory response in macrophages [30]. EAE mice deficient
for A-FABP and E-FABP (epidermal-fattyacid-binding-
protein) show reduced neurological symptoms and re-
duced cytokines production, suggesting a possible role of
this adipokine in the development of EAE/MS [31].
The highest A-FABP levels were observed in SPMS pa-
tients, with similar levels in RRMS patients and HC. In
patients with BMI < 50 the difference between SPMS
and HC was statistically significant for the model con-
trolling for age/batch, and controlling for BMI as well.
WAT and possibly monocyte production of A-FABP may
be present in SPMS, and may contribute to the pathogen-
esis of this disease subtype.
Our POMS patients had higher levels of A-FABP com-
pared to PHC, but this difference was not significant
when controlling for BMI, suggesting that BMI influ-
ences A-FABP levels. Interestingly, although leptin is in-
volved in the initiation of puberty, [32,33] we did not
find a difference in leptin levels between POMS and
healthy controls. POMS patients are characterized by a
higher relapse rates compared to AOMS patients [15].
Increased BMI at the age of 18 in females and at the age
of 20 in males has been related to an increased risk to
develop MS, consistent with the hypothesis that the ado-
lescence is a critical window for the development of MS
[3,34]. A recent study found increased BMI in female
POMS patients compared to demographically matched
controls, suggesting that BMI and possibly adipokines
may play a role in early-onset disease [35]. During pu-
berty, a state of low-grade inflammation and a conse-
quent increase in adipokine levels may predispose towards
autoimmunity.
We found a positive correlation between A-FABP and
leptin in RRMS and POMS, suggesting that possibly in
the early stage of the disease these adipokines are both
involved in the early inflammatory phase of disease, and
potentially disease development [36]. It is interesting thatthis correlation was not observed in the SPMS and PPMS
groups, raising the question of independent production of
these factors possibly by cells other than adipocytes in
later, progressive stages of disease.
Our study has several limitations. First, the relatively
small number of patients included, due to the difficulty
to obtain untreated patient samples. Second, leptin may
exhibit some diurnal variation with lowest levels in the
late afternoon [37], however our serum samples were
collected throughout the day in all subjects and controls.
Third, we could not control for Tanner staging, as these
data were not available in the age-matched PHC. While
all samples were selected from patients who had been
off DMT or intravenous steroids for at least 30 days, it is
possible that some DMT despite this washout may affect
adipokine levels. Finally in the pre-relapse and relapse
group analysis we did not confirm relapses by MRI.
Conclusions
To the best of our knowledge this is the first study to ex-
plore the role of leptin and A-FABP in progressive and
relapsing subcategories of untreated adult- and pediatric-
onset MS patients. We found the highest levels of A-FABP
and leptin in adult SPMS patients, suggesting an intrinsic
adipokines dysregulation in this disease subtype. We also
found increased A-FABP levels in pediatric MS patients,
which may be a marker of early inflammatory disease. Fur-
ther longitudinal studies are required to study the potential
for these adipokines to serve as biomarkers of disease pro-
gression, to monitor the effectiveness of therapy. Mechan-
istic studies addressing adipokine pathway mediators may
lead to the identification of novel therapeutics targets. Lon-
gitudinal studies investigating the role of adipokines in CIS
and POMS patients are needed to elucidate the interaction
between BMI, adipokines in the early stages of the disease.
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subgroups of MS patients (Pearson’s correlation).
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